Onyedika Ilonze, MD
Cardiovascular Disease · Indianapolis, INNPI 1174752554
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AstraZeneca at 31.5% of the total. 2025 is the largest year on record at $57,701, more than ten times the $2,471 reported in 2019. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $427.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$40K
- E.r. Squibb & Sons, L.L.C.$31K
- Bayer$15K
- Merck$9K
- Scpharmaceuticals Inc.$8K
- Novartis$8K
- plus $15K from 22 others
What the payments were for
- Consulting fees$49,95840%
- Speaking & faculty fees$57,90346%
- Travel & lodging$8,5427%
- Food & beverage$8,9417%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $39,509 |
| E.r. Squibb & Sons, L.L.C. | 50 | $31,369 |
| Bayer | 15 | $14,925 |
| Merck | 14 | $8,774 |
| Scpharmaceuticals Inc. | 2 | $8,196 |
| Novartis | 26 | $7,512 |
| Bridgebio Pharma, Inc. | 5 | $6,221 |
| Gilead | 3 | $2,682 |
| Abbott | 40 | $1,510 |
| Abiomed | 5 | $1,494 |
| Alnylam Pharmaceuticals Inc. | 10 | $628 |
| Medtronic | 2 | $550 |
| Actelion Pharmaceuticals US, Inc. | 26 | $505 |
| Pfizer | 14 | $356 |
| United Therapeutics Corporation | 10 | $314 |
| Bristol Myers Squibb | 1 | $300 |
| Novo Nordisk | 2 | $134 |
| Amgen | 7 | $103 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $90 |
| Baxter Healthcare | 1 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Johnson & Johnson | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$125,355 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 14 | $297,654 |
| AdempasRiociguat | 11 | $155,213 |
| Orenitram ErTreprostinil Diolamine | 12 | $123,591 |
| Ambrisentan | 22 | $77,140 |
| EntrestoSacubitril/Valsartan | 65 | $71,899 |
| JardianceEmpagliflozin | 72 | $65,435 |
| EliquisApixaban | 30 | $29,250 |
| FarxigaDapagliflozin Propanediol | 18 | $22,578 |
| Sildenafil Citrate | 31 | $14,573 |
| Tacrolimus | 82 | $10,576 |
| Mycophenolate Mofetil | 100 | $6,434 |
| Sirolimus | 19 | $5,397 |
| Cyclosporine ModifiedCyclosporine, Modified | 26 | $1,583 |
| Torsemide | 96 | $1,455 |
| Potassium Chloride | 74 | $1,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $505 | $297,65414 claims |
| BayerAdempas | $14,925 | $155,21311 claims |
| NovartisEntresto | $7,512 | $71,89965 claims |
| Boehringer IngelheimJardiance | $26 | $65,43572 claims |
| PfizerEliquis | $356 | $29,25030 claims |
| AstraZenecaFarxiga | $39,509 | $22,57818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Noel DasguptaIndianapolis$122K
- Anthony BashallIndianapolis$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.